Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker Asks High Court To Allow More Leeway In Awarding Triple Damages

This article was originally published in The Gray Sheet

Executive Summary

The device firm's opening brief in a Supreme Court patent case says a two-part test for enhanced damages imposed by the Federal Circuit is unconstitutional and should be struck down in place of greater judge discretion.

You may also be interested in...



High Court To Hear Stryker Patent Case On Willful Infringement Standards

The US Supreme Court will consider arguments on what standards should be met if an award in a patent violation case is to be increased due to willful infringement. A District Court judge tripled a $70 million award Stryker was granted against Zimmer for infringement in a jury trial, but the award was reduced on appeal.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel